On May 27, 2026 Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, reported the close of its seed financing. The close brings total capital raised to $6 million since the company’s founding in 2025. Investors include Unshackled Ventures, 1517 Fund, and Narya.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds will support continued development of the company’s lead program, expansion of its AI discovery engine, and CMC activities.

Reprogram Biosciences is developing a new class of therapeutics based on in situ cell reprogramming, where mRNA-encoded gene combinations, delivered directly into the tumor, activate the immune system by inducing antigen-presenting function in tumor cells. This approach is designed to transform the immunosuppressive tumor microenvironment into a site of active immune priming, with the goal of generating systemic antitumor immune responses.

"Many solid tumors remain difficult to treat despite advances in immunotherapy," said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. "Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents."

"This is a first-in-class approach to a problem that kills 10 million people a year, built by founders who moved from concept to in vivo data in six months with unparalleled capital efficiency," said Colin Greenspon, co-founder and partner at Narya. "That’s the kind of team and science Narya was built to back."

Reprogram identifies and prioritizes therapeutic reprogramming candidates with CellRecodeX, its AI discovery engine. CellRecodeX integrates multiple biological foundation models and is designed to support candidate nomination and pipeline expansion across indications.

(Press release, Reprogram Biosciences, MAY 27, 2026, View Source [SID1234666134])